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Conjugate vaccines are a major advance in
the control of diseases caused by two members of
the normal bacterial flora of the human
nasopharynx, Streptococcus pneumoniae (pneu-
mococcus) and Haemophilus influenzae type b
(Hib). In the absence of widespread vaccination,
pneumococci have been responsible for an
estimated 7 million cases of otitis media, 500,000
cases of pneumonia, 50,000 cases of bacteremia,
and 3,000 cases of meningitis each year in the
United States (1). Before the widespread use of
conjugate vaccines, Hib caused invasive disease
in an estimated 1 in 200 children <5 years of age
in the United States (2). Conjugate vaccines have
reduced the incidence of invasive Hib disease by
90% or more in industrialized countries (2,3).
After promising phase-II clinical trials (4-7), the
first results from a phase-III trial of a
pneumococcal conjugate vaccine have shown
very high efficacy against invasive disease (8).
In addition to protecting against disease,
conjugate vaccines protect against asymptom-
atic carriage of the target organisms (4-7,9).
H. influenzae and S. pneumoniae are frequently
found in the normal nasopharyngeal flora of
healthy persons, with invasive disease being
relatively rare compared with asymptomatic
carriage (10,11). Asymptomatic carriers are also
responsible for most transmission of these
organisms (10,11); in contrast to many other
vaccine-preventable infections, disease caused
by these organisms seems to contribute little to
the process of transmission (12-14). By reducing
the rate of carriage of targeted bacteria,
conjugate vaccines also reduce their transmis-
sion and should thereby offer protection to
unvaccinated contacts of vaccinated persons. It
has been shown (in the case of Hib) and
suggested (in the case of pneumococcus) that the
use of conjugate vaccines results in herd
immunity (15). Herd immunity may explain why
the reduction in invasive Hib disease in some
populations has exceeded the fraction of the
population that received the vaccine (3) and why
Hib invasive disease declined even in age groups
that had not yet received the vaccine (16).
Although the reduction in carriage achieved
by conjugate vaccines is beneficial from the
perspective of herd immunity, it has raised
concerns about the possibility of serotype
replacement. Both H. influenzae and pneumo-
cocci are characterized by extensive antigenic
diversity in their polysaccharide capsules. In
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H. influenzae, six capsular types are known, in
addition to a large group of nontypeable
(unencapsulated) variants. Before vaccination,
serotype b was responsible for most invasive
diseases, with minor contributions from the
other encapsulated types. Because of the
importance of Hib in invasive disease, vaccina-
tion efforts have concentrated on the b serotype
(16). Pneumococci are even more diverse, with 90
recognized serotypes; many of these serotypes
are capable of causing invasive disease. To
accommodate this greater diversity, pneumococ-
cal conjugate vaccines have incorporated
multiple serotypes. Because the protection
offered by conjugate vaccines is specific to the
capsular type(s) included in the vaccine, it has
been suggested that reducing carriage of these
vaccine types may leave open an ecologic niche
that will be filled by serotypes not included in the
vaccine (5,17-20).
Hib conjugate vaccines served as a model for
the development and testing of pneumococcal
vaccines. However, pneumococci are epidemio-
logically different from Hib, and results of
clinical trials with pneumococcal conjugates
suggest that the two bacteria differ in their
response to vaccination, especially with respect
to serotype replacement. This article describes
how mathematical models can be used to
elucidate these contrasting outcomes, specify the
conditions under which serotype replacement is
likely, interpret the results of conjugate vaccine
trials, design trials that will be better able to
detect serotype replacement (if it occurs), and
suggest factors to consider in choosing the
serotype composition of vaccines.
Serotype Replacement: Hib and
Pneumococcal Conjugate Vaccines
Serotype replacement has not been detected
since the introduction of Hib conjugate vaccines.
Studies of H. influenzae carriage in 700 children
in Finland (21) and 364 families in the United
Kingdom (15,22) found no evidence of increased
carriage of non-b H. influenzae as a result of
vaccination. Although increases in invasive
disease from other nasopharyngeal bacteria
have been reported since Hib vaccination began
(23,24), no evidence of a causal link to Hib
vaccination has been observed (22,23). Further-
more, a recent study in the United States showed
that the net impact of Hib vaccination has been a
68% reduction in invasive disease from all
H. influenzae between 1986 and 1995 (25);
therefore, any increase in disease from non-b
serotypes is small compared with the reduction
in disease from type b.
In contrast, pneumococcal conjugate vaccine
studies show considerable evidence of serotype
replacement, as measured by nasopharyngeal
carriage of nonvaccine type organisms. Increases
in the carriage of nonvaccine serotypes have
occurred in three major ongoing clinical trials of
pneumococcal conjugate vaccines. In Gambia,
carriage of nonvaccine serotypes was 79% in
children receiving three doses of a pneumococcal
conjugate vaccine (compared with 42.5% in
controls) (5). In trials of a 9-valent vaccine in
South Africa, carriage of nonvaccine serotypes
increased from 21% in controls to 39% in vaccine
recipients (6). Serotype replacement was
observed in the second of two large studies in
Israel (4,7); the reason for the difference in
outcome between the two studies remains
unclear. In the first phase-III trial for which data
were presented, no increase was observed in
invasive disease from nonvaccine types (8).
While this result is encouraging, it may not be
indicative of what will occur as conjugate
vaccines enter widespread use in a variety of
communities.
A Mathematical Model of Vaccination
against Colonizing Bacteria
Mathematical models can be useful in
defining the extent of serotype replacement in
various contexts, optimizing the design of
clinical trials to discern whether such replace-
ment occurs, and interpreting the results of
these trials. With these goals in mind, I
constructed and analyzed a mathematical model
of the transmission dynamics of colonizing
bacteria with multiple serotypes, such as
pneumococci, and the effect of vaccination on
these dynamics. The model is similar in
structure to the compartmental models used to
design and predict the effects of vaccination
programs against other infectious diseases (26).
The main distinguishing feature of this
model is that it simultaneously considers the
transmission of two (or more) strains of the same
organism. The model is designed to analyze the
effects of competitive interactions between these
strains, in which carriage of one serotype
reduces the probability that a host will be
colonized with another serotype. If such
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Figure 1. The structure of the mathematical model
described in the text and in greater detail (30).
competitive interactions occur, serotype replace-
ment is possible, because vaccine-induced
reductions in some serotypes will increase the
opportunities for others to spread in the
population. Epidemiologic studies have provided
indirect evidence of such competitive interac-
tions (27-29), while laboratory studies have
suggested mechanisms by which different
species of streptococci (30,31) or different strains
of H. influenzae (32) might compete in the
nasopharynx. At present, however, little is
known about the precise nature of these
interactions, and perhaps the most compelling
evidence that competition occurs comes from the
replacement observed in pneumococcal conju-
gate vaccine studies.
The assumptions and structure of the model
are as follows. In the absence of vaccination, the
model (Figure 1) assumes that humans are born
into the susceptible (X) compartment at a
particular rate and are removed from that
compartment (and all other compartments) at a
specific per capita death (or maturation) rate.
Two pneumococcal serotypes (designated 1
and 2) are present, and susceptible hosts may be
colonized by either type; colonization moves the
host into the Y1 or Y2 compartment, respectively.
The incidence of colonization with each type is
proportional to the total number of persons
carrying that type. Colonization has average
duration 1/γ. While carrying one serotype, a host
may be colonized by the other type, which moves
the host into the dually colonized compartment
(Y12). This secondary colonization also occurs at a
rate proportional to the prevalence of the
colonizing type, but a rate that is cj (j = 1 or 2)
times the rate at which a susceptible person
would be colonized by the same type. Thus, cj is
an inverse measure of the competitive inhibition
of type j by the resident type in a host.
When vaccination begins, a fraction f of all
persons are assumed to be vaccinated at birth. In
the model, these persons are born into the
vaccinated (V) compartment. It is assumed that
vaccination completely protects a person against
carriage of type 1 (this is done to simplify the
analysis of the model; if only partial protection
were offered, the effects would be similar to those
observed at a lower level of vaccine coverage f).
To consider the effects of including more than
one bacterial serotype in the vaccine, the model
can accommodate vaccines that are effective only
against type 1 (monovalent vaccines), as well as
those that give either partial or full protection
against type 2 (bivalent vaccines). The param-
eter k represents the degree of protection offered
by the vaccine against serotype 2.
By varying the parameters of the model, it is
possible to compare the effects of different levels
of vaccine coverage (fractions of the population
vaccinated), different assumptions about the
competitive interactions among pneumococcal
serotypes, and different types of vaccines
(monovalent vs. bivalent) (33). In summary, the
major predictions of the model are as follows.
1) If there is competition between different
pneumococcal serotypes to colonize hosts,
vaccination against serotype 1 alone will
increase the prevalence of serotype 2. The extent
of replacement, measured as the increase in the
prevalence of serotype 2, will be greatest when
vaccine coverage is high and when serotype 2 is
strongly inhibited from colonizing persons who
carry serotype 1. Serotype replacement may take
either of two forms: an increase in prevalence of
a type already present in the population or the
appearance and spread of types previously
absent from the population because they were
unable to compete with the vaccine type(s).
2) Bivalent (or polyvalent) vaccines can also
cause replacement if the protection offered
against different serotypes is uneven. In
particular, if a vaccine has relatively low efficacy
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Figure 2. Carriage of three serotypes of Haemophilus
influenzae in children vaccinated against serotype b
(white bars) and in controls (black bars) (14). Error
bars indicate 95% confidence interval (binomial
approximation). Shaded bars show the maximum
carriage of serotypes e and f in vaccine recipients that
could result from replacement in a population where
only a small proportion of susceptibles are vaccinated
(as in the study). Striped bars show the equivalent
figures in a hypothetical study in which virtually all
susceptibles were vaccinated.
against serotype 2 but very high efficacy against
serotype 1, use of a bivalent vaccine may increase
the prevalence of type 2.
3) If only two serotypes interact in a
population, the amount of replacement that can
occur is limited. Specifically, the increase in the
prevalence of serotype 2 will always be less than
or equal to the decrease in the prevalence of
serotype 1. Thus, for example, if the prevalences
of serotypes 1 and 2 before vaccination are 15%
and 20%, respectively, then the prevalence of
serotype 2 after vaccination will be no more
than 35%.
4) If more than two types are competing to
colonize hosts, this limitation need not hold. In
the presence of more than two types, vaccination
can increase the prevalence of a single,
nonvaccine type more than it reduces the
prevalence of the vaccine type.
 5) Although replacement is of concern, it
may also be beneficial. If serotypes compete to
colonize hosts, increases in the prevalence of the
nonvaccine types will help reduce the prevalence
of the serotypes included in the vaccine. Thus,
replacement will augment the effects of herd
immunity in reducing the exposure of all
members of the population to vaccine serotypes.
This results in a tradeoff between the breadth of
coverage of a vaccine (number of serotypes
covered) and the effectiveness of the vaccine in
reducing carriage of each serotype at the
population level.
The models predictions have several
implications for the interpretation of existing
data from the use of conjugate vaccines, the
design of vaccine trials, and the choice of vaccine
composition.
Why Has Replacement Carriage Occurred
with Pneumococcal Conjugate Vaccines
but Not with Hib Vaccines?
As noted above, the absence of serotype
replacement observed with the use of Hib in
industrialized countries contrasts with the
findings of considerable serotype replacement in
two studies of pneumococcal vaccines. What
might account for this difference?
The mathematical model suggests an
explanation. The model predicts that, in a
pairwise interaction between two serotypes, the
increase in prevalence of a nonvaccine type will
be no more than the reduction in prevalence of a
vaccine serotype. This principle is illustrated in
Figure 2, which presents data from a study of Hib
conjugate vaccine in the United Kingdom (15). In
the figure, the white bars show the prevalence of
each of three H. influenzae serotypesb, e, and
fin vaccinated persons, and the black bars
show the prevalence of each of these serotypes in
controls. If one assumes that Hib interacts
independently with each of the two nonvaccine
serotypes (e and f), one can use the two-serotype
model to calculate the maximum prevalence of
these nonvaccine types in vaccinees that would
be expected if these serotypes compete very
strongly with serotype b. The striped bars show
the maximum prevalence of types e and f
expected in the study, where only a small
fraction of the community was vaccinated; the
shaded bars indicate the equivalent figure if the
whole community had been vaccinated. As is
clear from the figure, the increase in nonvaccine-
type carriage in vaccinees would be minuscule
and statistically undetectable in a study of this
kind (indeed, the study from which these data
were drawn was not designed to detect
replacement; data on the prevalence of types e
and f were used to control for general changes in
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the prevalence of H. influenzae that could have
been attributable to factors other than vaccina-
tion [15]). The reason is that the prevalence of
Hib was so low before vaccination that even its
complete removal by widespread vaccination
would have little effect on competing bacteria.
The prevalence of Hib carriage in other
industrialized countries is similar to that
measured in the UK study. Therefore, the model
suggests that the lack of replacement, even after
widespread use of the Hib conjugate vaccine in
industrialized countries, may be a simple result of
the low prevalence of Hib carriage.
If this interpretation is correct, then
serotype replacement would be more likely to
occur in areas where the prevalence of Hib is
higher or for vaccination against other
organisms whose prevalence is higher. This
difference could account for the contrasting
outcomes of vaccination against Hib and
pneumococci. Differences in the biology of
colonization or in the interactions between
bacterial types may also have a role in these
contrasting outcomes. Distinguishing the rela-
tive importance of these two explanations will
require further research into the biologic
interactions of bacterial populations in the
nasopharynx, as well as studies of the effects of
conjugate Hib vaccination in areas where Hibs
prevalence is higher.
Detection of Replacement: The
Design of Clinical Trials
If used by a large fraction of the human
population in a community, a conjugate vaccine
may alter the composition of the bacterial
population, not only in vaccinated, but also in
unvaccinated persons in that community.
Vaccination may reduce the prevalence of
serotypes included in the vaccine, thereby
protecting unvaccinated persons against expo-
sure to these serotypes (herd immunity).
Similarly, if serotype replacement occurs and
vaccinated persons become more likely to carry
nonvaccine serotypes, the exposure of unvacci-
nated persons to these serotypes will increase. As
a result of these indirect effects, strain
replacement will be magnified in communities
where large numbers of persons are vaccinated.
This process is also evident from Figure 2.
There, the striped bars show the models
prediction of the maximum increase in non-
vaccine type carriage in vaccine recipients in a
community in which the vaccine is used only on
a very small proportion of the population, while
the shaded bars show the same increase in a
community where everyone is vaccinated. As is
clear from the figure, replacement will be most
easily observed in communities where the level
of vaccine coverage is high.
Therefore, one would expect that the extent
of serotype replacement when vaccines enter
widespread use in a community may be much
greater than that observed in clinical trials
where a relatively small fraction of the
community is immunized. This is one important
reason why the failure to observe an increase in
invasive disease from nonvaccine-type pneumo-
cocci in the Northern California trial (8), while
promising, may not be indicative of the potential
for replacement once the vaccine is used on a
large scale. If one is interested in designing a
clinical trial that simulates the selective
pressures exerted by communitywide use of a
conjugate vaccine, and therefore maximizes the
chances of observing serotype replacement
during the trial, then community-randomized
clinical trials will be superior to individually
randomized ones. Studies of pneumococcal
vaccines in which communities are the units of
randomization are under way in Native
American communities in the southwestern
United States (K. OBrien, pers. comm.).
Vaccine Composition:
Replacement Revisited
For an organism like pneumococcus, in which a
number of serotypes can cause disease, the
choice of serotypes for inclusion in a conjugate
vaccine is critical. One strategy would be to
include as many serotypes as possible to achieve
the broadest possible protection. In addition to
some clinical limitations on the number of
serotypes that can be included in a single
vaccine, there are other reasons why such a
strategy would not be ideal. As noted above in the
last prediction from the model, serotype
replacement can augment the effectiveness of a
vaccination program in a community. This
occurs because increases in the prevalence of
nonvaccine serotypes competitively inhibit
carriage of vaccine serotypes. Ideally, then, one
would like to design a vaccine that maximizes
these beneficial effects while minimizing the risk
of added disease from increased carriage of
nonvaccine serotypes.
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The question is how to accomplish such a
balance. So far, the model describes only carriage
of various serotypes; it does not directly address
the problem of disease. The effect of vaccination
on disease will depend both on changes in
patterns of carriage of different serotypes and on
the propensity of the individual serotypes to
cause disease. Serotypes of H. influenzae and
S. pneumoniae vary considerably in their
pathogenicity, as manifested by experimental
evidence (34) and by differences between the
frequency of particular serotypes in carriage
isolates and their frequency in disease isolates
(17,35). If these serotype associations were
stable, the ideal vaccine could simply include the
most pathogenic serotypes but exclude those that
tend to be avirulent, thereby taking advantage of
any increases in the prevalence of the avirulent
serotypes to augment the effect of the vaccine (36).
This approach has several limitations. First,
the model predicts that widespread use of a
vaccine may result in the appearance of bacterial
types which, before vaccination, had been absent
from the population because of competition from
vaccine types. The virulence of these novel types
would be difficult to predict, since competitive
inferiority to existing types need not be
correlated with low virulence (12,13). Second,
both species discussed here are highly trans-
formable. Although capsular type seems to be
very closely associated with virulence in
H. influenzae (34,37), transformation studies in
pneumococci have shown complicated interac-
tions between capsular type and other genes in
determining virulence (38), so the existing
associations between virulence and capsular
type in pneumococci (39,40) may change in
response to conjugate vaccine-induced selective
pressure. If such vaccines are used on a
widespread scale, surveillance of shifts in the
serotype associations of invasive disease should
be maintained.
Serotype replacement has been discussed
primarily as it applies to serotypes not included
in the vaccine. However, if the vaccine is only
weakly effective in immunizing against carriage
of some of the serotypes included in it, even these
serotypes may increase in prevalence after
vaccination is introduced. This can occur if the
efficacy of the vaccine against these serotypes is
outweighed by its effect in removing competing
serotypes. Results of trials published thus far
indicate that the protection offered by the
vaccine against included serotypes taken
together is considerably lower than 100%.
Therefore, the results of future trials should be
monitored to determine whether prevalence of
any of the individual vaccine serotypes is
increasing in vaccinated hosts.
Interpreting Replacement: Is It Real?
Studies of pneumococcal carriage are
typically performed by sampling the nasopha-
ryngeal flora of vaccinated and unvaccinated
persons, plating the samples on agar, and
serotyping one or a few colonies. This technique
typically identifies the most abundant pneumo-
coccal serotypes carried by a person, and possibly
a minority type if it is present in large numbers.
However, many people carry more than one
pneumococcal type (27,41), and when the
pneumococci are studied in detail, the minority
type may be much less plentiful than the
majority typeat a frequency of 10% or less (41).
Therefore, current methods are likely to have
very low sensitivity for the detection of minority
types.
This creates a problem in measuring
serotype replacement during pneumococcal
vaccine trials. Vaccinated persons, who are
protected against carriage of vaccine types, may
become more susceptible to carriage of pneumo-
coccal types not included in the vaccine. This is
serotype replacement, a phenomenon that
vaccine trials are intended, in part, to detect. In
addition, nonvaccine type pneumococci, even if
they are not more plentiful, may be more readily
detected in vaccinated persons. Some unvacci-
nated persons carry both vaccine-type and
nonvaccine-type pneumococci, and in some of
them, the vaccine-type will be in the majority.
Because minority populations of pneumococci
are difficult to detect, the nonvaccine-type
pneumococci carried by these persons is masked
by the vaccine types, resulting in an underesti-
mate of the prevalence of nonvaccine-type
pneumococci in the unvaccinated population.
Vaccinated persons, by contrast, are less likely to
carry vaccine-type pneumococci, so their
nonvaccine-type pneumococci are more likely to
be detected. This is known as unmasking.
Figure 3 illustrates the distinction between
serotype replacement and unmasking. Unmask-
ing is an artifact of sampling, and one would like
to be able to determine whether a finding of
higher nonvaccine-type carriage rates in
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Figure 3. Two hypotheses explain the observation of higher rates of carriage
of nonvaccine serotypes in vaccine recipients than in controls. Large circles
represent plated samples from controls (top) andvaccine recipients
(bottom). The left side shows true serotype replacement; here a control
carries vaccine types (white colonies), while a vaccine recipient does not,
and (possibly as a result of decreased competition) now carries only
nonvaccine types (black colonies). The right side shows the unmasking
phenomenon, which is an artifact of sampling. Here, both vaccinees and
controls carry nonvaccine types, but because only one colony is sampled in
each, the vaccinee does not appear to carry nonvaccine types.
vaccinated persons reflects true serotype
replacement, unmasking, or a combination of
these phenomena.
I have recently developed a statistical
procedure to answer this question (M. Lipsitch,
submitted for publication). The procedure
attempts to detect serotype replacement by
attempting to reject a null model that
incorporates the effect of unmasking alone. In
short, if the increase in nonvaccine type carriage
in vaccinees, compared to controls, is greater
than can be accounted for by this null model,
then one concludes that additional factors,
presumably serotype replacement, must be
responsible for the observed increase. This
technique has been applied to two datasets, one
from South Africa (6) and one from Gambia (5).
In both cases, the observed increase was greater
than that expected from unmasking alone. In the
South African case, the difference was statisti-
cally significant (p = 0.02), but it was not in the
Gambian dataset (p = 0.085). However, the
Gambian dataset was extremely small and some
information was unavailable for this dataset that
might have improved the power of the test. The
test is simple to perform using
the BUGS software (42,43)
available free on the World Wide
Web (http://www.mrc-
b s u . c a m . a c . u k / b u g s / W e l
come.html) and a program
available from the author;
thus, it may be readily applied
to future datasets.
Limitations of
Mathematical Models
The mathematical mod-
els described here, like all such
models, involve a number of
simplifications. In some cases,
these simplifications are intro-
duced to make the model more
tractable and focus attention
on fundamental processes of
transmission and competition
between serotypes. In other
cases, the simplifications are
necessary because much re-
mains unknown about the
biologyand especially the
immunologyof carriage of
these organisms. The assump-
tions of the model are discussed at greater length
(33). One of these assumptions will be considered
here in greater detail to highlight some areas
where additional knowledge of the biology of
pneumococcal-host interactions is most needed.
The model assumes that bacteria of different
serotypes compete via direct interactions in the
nasopharynx. These interactions may take the
form of competition for resources, such as
attachment sites or nutrients, or they may take
the form of interference competition, in which a
resident type produces substances toxic to other
bacteria that may attempt to colonize the same
host. Apart from the few studies cited above,
little is known about either the intensity or the
mechanisms of such inhibition. There are some
epidemiologic data that indirectly indicate the
existence of such competitive interactions. A
study of military personnel in 1946 (27) used a
very sensitive technique, mouse inoculation, to
detect nasopharyngeal carriage of one or more
pneumococcal serotypes. The numbers of
persons carrying one, two, three, or four
serotypes are given, and although the published
data do not provide all of the information
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necessary for formal statistical inference, the
pattern suggests that interference between
serotypes may have occurred.
The model does not take into account
acquired immunity to carriage of these bacteria,
or the possibility that carriage of one serotype
may inhibit future carriage of another serotype,
even after the first is no longer carried. It is
unclear to what degree it is realistic to ignore
acquired immunity to carriage. While carriage
has been shown to induce a serum antibody
response in at least one report (44), it is less clear
whether such responses affect carriage at the
nasopharyngeal mucosa. The success of conju-
gate vaccines in reducing carriage indicates that
some antibody responses can affect carriage.
However, it remains to be demonstrated whether
such responses are induced by natural exposure
through the respiratory route, whether natural
exposure induces responses to other, more
conserved antigens or only to the capsular
antigen, and whether natural exposure induces
long-lived immunologic memory. Preliminary
results of mathematical models that incorporate
naturally acquired immunity to carriage suggest
that the expected effects of vaccination on the
serotype composition of the population may be
different from those expected under the models
described here. Therefore, further research into
the microbiology and immunology of the host-
bacterial relationship in the nasopharynx will be
critical to understanding and predicting the
population-wide effects of conjugate vaccines.
Additional Considerations
The choice of serotypes for inclusion in
conjugate vaccines has been different in different
locations but has generally been designed to
cover serotypes that are most often implicated in
invasive disease. Often, these types coincide
with serotypes showing the greatest levels of
antibiotic resistance (45,46). As a result,
conjugate vaccination has led to a reduction in
the percentage of antibiotic-resistant pneumo-
cocci carried by vaccinees (4,6).
In principle, replacement could occur with
bacteria that differ from the vaccine targets not
only in serotype but in species. Indeed, one of the
studies of bacterial antagonism in the nasophar-
ynx concentrated on interactions between
species rather than between serotypes of the
same species (30). Furthermore, even if
replacement is limited to members of the same
species, the serotypes that increase may tend to
cause a disease different from that caused by
vaccine-type organisms (e.g., otitis rather than
pneumonia or bacteremia). Therefore, as
conjugate vaccines are used, changes in diseases
attributable to organisms that colonize the
nasopharynx should be monitored.
Finally, capsular polysaccharide is not the
only possible target for vaccination. Several
pneumococcal vaccines based on protein anti-
gens are in various stages of testing (47).
Because these protein antigens show consider-
ably less variation among pneumococcal isolates,
vaccines based on them should be less vulnerable
to serotype replacement and may be useful as
complements or alternatives to polysaccharide
conjugate vaccines.
Conclusions
The occurrence of serotype replacement in
three trials of pneumococcal conjugate vaccines
confirms the validity of concerns expressed in
anticipation of these trials. As the results of more
clinical trials become available, it will become
clearer how general this phenomenon is.
Mathematical models are useful in suggesting
ways to improve the design of these trials and the
interpretation of their results.
The extent and importance of serotype
replacement will depend on many locally
variable factors, the prevalence of vaccine-type
organisms before vaccination, and the level of
vaccine coverage. This prediction underscores
the need for continuing studies of vaccination in
different communities and for at least some
studies in which a substantial fraction of a
community receives the vaccine. Furthermore,
the epidemiologic findings of these studies
should be the impetus for further research into
the role of serotype and other factors in
determining the variation in pneumococcal
virulence, the nature of immune responses to
organisms like the pneumococcus at the
nasopharyngeal mucosal surface, and other
questions in the biology of bacterial carriage.
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